Advertisement
Australia markets closed
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • AUD/USD

    0.6504
    +0.0015 (+0.23%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.94
    -0.42 (-0.50%)
     
  • GOLD

    2,333.80
    -8.30 (-0.35%)
     
  • Bitcoin AUD

    101,470.16
    -209.75 (-0.21%)
     
  • CMC Crypto 200

    1,429.24
    +5.14 (+0.36%)
     

Can CureVac Win Market Share With Only 48% Vaccine Efficacy?

Can CureVac Win Market Share With Only 48% Vaccine Efficacy?

CureVac (NASDAQ: CVAC) surprised investors a few weeks ago when it announced disappointing data from a trial of its mRNA vaccine candidate. Many expected the German biotech would follow in the footsteps of fellow mRNA vaccine makers Pfizer and Moderna. After the CureVac report, it looked like company's dreams of a spot in the vaccine market were over -- at least in the near term.